Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Health Systems, Economic Evaluations, Quality of Life, and Functional Brain Connectivity Studies.
Donanemab: Appropriate use recommendations
Relationships of PGRN with sTREM2 in AD continuum and non-AD pathophysiology and their reciprocal roles in modulating amyloid pathology: two population-based study
Sleep chart of biological aging clocks in middle and late life
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Differences in baseline cognitive performance between participants with early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI
A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce
Plasma Aβ42/Aβ40 and phospho‐tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
Natural cubic splines for the analysis of Alzheimer's clinical trials
Sex and <i>APOE ε4</i> carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease
Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection
Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study
Designing the next-generation clinical care pathway for Alzheimer’s disease
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI)
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under‐represented populations
Tau positron emission tomography in preclinical Alzheimer’s disease
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology
Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals
Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention